Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
QuantumPharm, Inc. ( (HK:2228) ) just unveiled an announcement.
XtalPi Holdings Limited announced that it expects its 2024 revenue to reach HK$250,000,000, positioning it to potentially transition from a Pre-Commercial to a Commercial Company under Hong Kong Stock Exchange rules. The announcement highlights the company’s growth driven by its drug discovery and intelligent automation services, though the results are based on unaudited accounts and may differ from final audited results.
More about QuantumPharm, Inc.
XtalPi Holdings Limited, formerly known as QuantumPharm Inc., operates in the pharmaceutical industry, providing drug discovery and intelligent automation solutions. The company is focused on leveraging business developments and market opportunities to advance its offerings and reach significant revenue milestones.
YTD Price Performance: 10.54%
Average Trading Volume: 119,281,280
Technical Sentiment Consensus Rating: Strong Sell
For a thorough assessment of 2228 stock, go to TipRanks’ Stock Analysis page.
